Hemay181

Phase 1Small molecule

GGanzhou Hemay Pharmaceutical Co., Ltd

Hemay181 is one of 79 small molecule programs targeting Efficacy and Safety. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyRecruiting

Patients With Advanced Solid TumorsRecruiting

Efficacy and SafetyPhase 1

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

26 2

Eloxatin

Teva

Phase 2

9 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

23 4

Paraplatin

AAvyxa

Phase 2

22 5

Camptosar

Pfizer

Phase 2

4 6

Yervoy

Bristol-Myers Squibb

Phase 2

4 7

Halaven

Eisai

Phase 2

2 8

Kisqali

Novartis

Phase 2

2 9

Erbitux

Aldactone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Efficacy and Safety

NCT07446816

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181

Recruiting·GGanzhou Hemay Pharmaceutical Co., Ltd·Phase 1·NCT07446816·24 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors

Recruiting·GGanzhou Hemay Pharmaceutical Co., Ltd·Phase 1·NCT05749432·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Hemay181. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hemay181 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hemay181. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ganzhou Hemay Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGanzhou Hemay Pharmaceutical Co., Ltd

Hemay181

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Efficacy and Safety1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News